Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. uri icon

authors

  • Yang, Huaiyu
  • Papakostas, George I
  • Sinicropi-Yao, Lara
  • Sarah Chuzi, MD, MSc
  • Youn, Soo Jeong
  • Clain, Alisabet
  • Baer, Lee
  • Chen, Ying
  • McGrath, Patrick J
  • Fava, Maurizio

publication date

  • February 26, 2010